ArticleVeterinary research communications2024
Antimicrobial and anti-biofilm efficacy of different inorganic and organic zinc forms against multidrug-resistant Escherichia, Klebsiella, Staphylococcus and Pseudomonas.
Article in Veterinary research communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
- Virulence profiling and biofilm-forming capacity of differentVeterinary and animal science · 2026Article
- Reconstructing the Antibiotic Pipeline: Natural Alternatives to Antibacterial Agents.Biomolecules · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In our study antibacterial and anti-biofilm efficacy of 2 inorganics (Zn(II) sulphate monohydrate; Zn(II) sulphate heptahydrate) and 3 organic Zn(II) substances (Zn(II) chelate of protein hydrolysate: Zn-Bio; Zn(II) chelate of amino acid hydrate: Zn-AMK; Zn(II) chelate of glycine hydrate: Zn-Gly) were explored and compared against multidrug resistant Escherichia coli (E. coli), Staphylococcus aureus (S. aureus), Klebsiella oxytoca (K. oxytoca) and Pseudomonas aeruginosa (P. aeruginosa) using by the 96- wells microtiter plate-based resazurin and/or crystal violet assay. Our finding confirmed that Zn(II)-sulphates and Zn(II)-amino acid complexes exhibit dose and genus-based antibacterial and anti-biofilm potential. Organic compounds (Zn-AMK and Zn-Gly) were more effective against bacterial growth, except P. aeruginosa. Besides Zn-AMK, others organic and inorganic forms of Zn(II) caused predominantly statistically significant decrease of biofilm production in all of tested bacteria. Current data highlights that Zn(II) in various forms has a great potential to be developed as antibacterial and anti-biofilm agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.